Back to top

Analyst Blog

Peregrine Pharmaceuticals (PPHM - Snapshot Report) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III registration trial for its oncology candidate, bavituximab.

Peregrine Pharma is evaluating bavituximab for the second-line treatment of non-small cell lung cancer (NSCLC). Data from a phase IIb trial in patients treated with bavituximab plus Sanofi’s (SNY - Analyst Report) Taxotere (docetaxel) helped determine the phase III trial design.

The randomized, double-blind, placebo-controlled phase III trial (n=600) will be conducted across the world among stage IIIB/IV non-squamous NSCLC patients, whose disease progressed after standard front-line treatment, with the primary endpoint being overall survival. The study will compare bavituximab plus Taxotere to Taxotere alone.

We note that bavituximab is a key pipeline candidate at Peregrine Pharma. In addition to second-line NSCLC, bavituximab is being studied for other indications including front-line NSCLC, front-line pancreatic cancer, breast, liver and rectal cancers.

The agreement of a phase III trial design by the FDA is a major relief for Peregrine Pharma considering the controversy surrounding bavituximab’s phase II results. Last year, the company had presented results on bavituximab from a phase II study for second-line non-small cell lung cancer. However, later on, Peregrine Pharma had said that the data could not be relied on due to certain discrepancies between some patient sample test results and patient treatment code assignments.

Then, earlier this year, Peregrine Pharma provided an update on the situation and gave information from an internal review of the discrepancies and said that discrepancies were isolated to the placebo and 1 mg/kg treatment arms of the trial with no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.

We expect investor focus to remain on updates on the future development path for bavituximab. The successful development and commercialization of bavituximab would be a major positive for Peregrine Pharma which currently has no approved drug.

Peregrine Pharma currently carries a Zacks Rank #3 (Hold). Right now, Anika Therapeutics, Inc. looks attractive with a Zacks Rank #1 (Strong Buy).Celgene Corporation (CELG - Analyst Report) also looks well placed with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%